108 related articles for article (PubMed ID: 24987911)
21. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
22. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.
Pectasides D; Fountzilas G; Papaxoinis G; Pectasides E; Xiros N; Sykiotis C; Koumarianou A; Psyrri A; Panayiotides J; Economopoulos T
Int J Gynecol Cancer; 2009 May; 19(4):777-81. PubMed ID: 19509587
[TBL] [Abstract][Full Text] [Related]
23. A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
Downs LS; Judson PL; Argenta PA; Carson LF; Boente MP
Gynecol Oncol; 2004 Nov; 95(2):347-51. PubMed ID: 15491756
[TBL] [Abstract][Full Text] [Related]
24. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.
Li Y; Zeng J; Huang M; An J; Bai P; Wu L; Zhang R
Cancer; 2017 Feb; 123(3):420-425. PubMed ID: 27696395
[TBL] [Abstract][Full Text] [Related]
25. [The course of squamous cell carcinoma antigen and CEA as prognostic criteria for response to chemotherapy in cervix cancer].
Meier W; Eiermann W; Stieber P; Fateh-Moghadam A; Hepp H
Geburtshilfe Frauenheilkd; 1989 Dec; 49(12):1050-5. PubMed ID: 2693187
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM
Semin Oncol; 2000 Feb; 27(1 Suppl 1):36-40. PubMed ID: 10697043
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
[TBL] [Abstract][Full Text] [Related]
29. Advances in cervical cancer pharmacotherapies.
Markman M
Expert Rev Clin Pharmacol; 2014 Mar; 7(2):219-23. PubMed ID: 24490716
[TBL] [Abstract][Full Text] [Related]
30. Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.
Brave M; Dagher R; Farrell A; Abraham S; Ramchandani R; Gobburu J; Booth B; Jiang X; Sridhara R; Justice R; Pazdur R
Oncology (Williston Park); 2006 Oct; 20(11):1401-4, 1410; discussion 1410-11, 1415-6. PubMed ID: 17112001
[TBL] [Abstract][Full Text] [Related]
31. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Benner SE; Lippman SM; Huber MH; Hong WK
Semin Oncol; 1995 Oct; 22(5 Suppl 12):22-5. PubMed ID: 7481857
[TBL] [Abstract][Full Text] [Related]
33. In vitro responses of ovarian cancers to platinums and taxanes.
Kornblith P; Wells A; Gabrin MJ; Piwowar J; Chattopadhyay A; George LD; Ochs RL; Burholt D
Anticancer Res; 2003; 23(1B):543-8. PubMed ID: 12680143
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
[TBL] [Abstract][Full Text] [Related]
35. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
[TBL] [Abstract][Full Text] [Related]
37. Recurrence patterns after radical hysterectomy in stage IB1-IIA cervical.
Sittidilokratna K; Cheewakriangkrai C; Khunamornpong S; Siriaunkgul S
Asian Pac J Cancer Prev; 2010; 11(2):499-502. PubMed ID: 20843140
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma.
Scandurra G; Scibilia G; Banna GL; D'Agate G; Lipari H; Gieri S; Scollo P
J Gynecol Oncol; 2015 Apr; 26(2):118-24. PubMed ID: 25686397
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
40. The role of paclitaxel in the management of patients with carcinoma of the cervix.
Thigpen T; Vance R; Khansur T; Malamud F
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-41-S2-46. PubMed ID: 9045336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
